Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs.

BACKGROUND

We investigated the incidence of chronic kidney disease (CKD) progression and its factors relevant to patients with stable rheumatoid arthritis (RA).

METHODS

We enrolled consecutive patients with RA who had initiated treatment with a biologic disease-modifying anti-rheumatic drug (bDMARD) at our institution and continued the same drug for >5 years between 2001 and 2016. Patients with CKD at bDMARD initiation were excluded. C-reactive protein (CRP) level, Clinical Disease Activity Index (CDAI) score and estimated glomerular filtration rate were measured every 6 months.

RESULTS

We included 423 patients, with 196 on tumour necrosis factor inhibitors, 190 on tocilizumab and 37 on abatacept. Among these patients, 34 (8.0%) progressed to CKD within 5 years. The mean CRP level and CDAI score over 5 years were significantly lower in patients without CKD progression than in those with CKD progression ( < .001 and  = .008, respectively). Multivariable analysis revealed that age at bDMARD initiation [odds ratio (OR) 1.05,  = .002], non-steroidal anti-inflammatory drug use (OR 3.47,  = .004) and mean CRP >0.14 mg/dL (OR 5.89,  = .015) were independently associated with CKD progression, while tocilizumab use was associated with a decreased risk of CKD progression (OR 0.31,  = .027).

CONCLUSIONS

Controlling inflammation contributes to the inhibition of CKD progression in RA patients.